| Symbol | TSX : AMB |
|---|---|
| Last trade | 0.07 |
| Volume | 20,620 |
| As of | 2008-11-20 13:07 EST |
| Note: Quotes are delayed. For informational purposes only. |
|
Investors
Profile and Strategy
Ambrilia Biopharma Inc. is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer.
Ambrilia’s strategy is to capitalize on its broad product portfolio and original expertise in virology. The Company has elected to prioritize its divestment strategy of monetizing (selling or licensing) its oncology assets with cost-cutting actions which resulted in a hold on its antiviral R&D activities. The divestment strategy aims to generate non-dilutive R&D funding for Ambrilia, preserve its cash flow and extend the runway to financing.
Recent Highlights
- Octreotide C2L
Results from two Phase III clinical trials (301 and 302) support its ability to replace Sandostatin LAR® with less frequent injections and non inferior efficacy, and comparable safety.
Expanded divestment opportunity with termination of U.S. license for a one time payment of $US1.2M. - Goserelin
Expanded product offering with novel 1-month formulation.
Initiated Phase I/II clinical program (3-month formulation) in prostate cancer. - NGR-Delivery Technology
Completed the in vivo proof-of-concept applied to a siRNA.